Crohn’s disease

Unraveling the Paradox: Why Smoking Benefits Ulcerative Colitis but Worsens Crohn’s Disease

By MedXY 09/04/2025

Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.

Clinical Updates Gastroenterology Specialties

Guselkumab for Crohn’s Disease and Ulcerative Colitis: Efficacy and Safety from Recent Phase 3 Trials

By MedXY 08/02/2025

Phase 3 studies demonstrate guselkumab's efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn's disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.

Clinical Updates Gastroenterology news Specialties

EASE-CD: A Validated Endoscopic Ulcer Activity Score for Crohn’s Disease—Clinical Utility and Evidence from Randomized Trials

By MedXY 08/02/2025

The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn's disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.